In December 2019, Ubrogepant (UBRELVY) received approval by the FDA for the treatment of migraine with or without aura. It is an antagonist of calcitonin gene-related peptide receptor. Ubrogepant contains aminopiperidin-2-one moiety in its backbone. We have made a set of Building Blocks, which contain this heterocycle – perfect start for your research!